Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine
Recruiting
Phase 4
Interventional Study
Postoperative Pain Management
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 120 (estimated)
- Sponsor
- Rhode Island Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients undergoing elective total hip arthroplasty
* 18-80 years old
* ASA 1-3 classifications
Exclusion Criteria:
* ASA classification of 4 or greater
* Infection at the site of nerve blockade
* Coagulopathy
* Known allergy to study medications
* Chronic opioid consumption…
Contacts